Literature DB >> 7333866

Chronic granulomatous disease: effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function.

R A Seger, S Baumgartner, L X Tiefenauer, F K Gmünder.   

Abstract

Normal and chronic granulomatous disease (CGD) neutrophils accumulated sulfamethoxazole (SMX) 3-fold and trimethoprim (TMP) 14-fold, possibly through a non-ionic diffusion and pH-partition mechanism. CGD neutrophils incubated with SMX/TMP after phagocytosis of S. aureus killed the bacteria. These findings explain the clinically observed beneficial effect of SMX/TMP in the treatment of infections in CGD and in other conditions characterized by impaired phagocyte microbicidal capacity.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7333866

Source DB:  PubMed          Journal:  Helv Paediatr Acta        ISSN： 0018-022X


  8 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Antimicrobial therapy of experimental Legionella micdadei pneumonia in guinea pigs.

Authors:  A W Pasculle; J N Dowling; F N Frola; D A McDevitt; M A Levi
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  Penetration of brodimoprim into human neutrophils and intracellular activity.

Authors:  P C Braga; M Dal Sasso; S Maci; G Bondiolotti; E Fonti; S Reggio
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Another look at trimethoprim-sulfamethoxazole: its role in parenteral therapy.

Authors:  F R Sattler; J S Remington
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

5.  Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes.

Authors:  P H Höger; K Vosbeck; R Seger; W H Hitzig
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

6.  Microfluidic arenas for war games between neutrophils and microbes.

Authors:  Felix Ellett; Fatemeh Jalali; Anika L Marand; Julianne Jorgensen; Baris R Mutlu; Jarone Lee; Adam B Raff; Daniel Irimia
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

7.  The management of chronic granulomatous disease.

Authors:  A Fischer; A W Segal; R Seger; R S Weening
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

8.  Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease.

Authors:  S Kloss; A Schuster; H Schroten; J Lamprecht; V Wahn
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.